We are pleased to announce that Jennifer Che, Managing Director of Eagle IP, will be attending the American Intellectual Property Law Association (AIPLA) 2026 Spring Meeting. She will also be participating as a speaker at the AIPLA Chemical Patent Practice Institute, presenting on the China perspective at an international panel on written description. The Chemical Patent Practice Institute will take place from May 11 to 12, while the Spring Meeting will take place from May 13 to 15, 2026, at the historic Fairmont San Francisco.

As one of the most significant gatherings for intellectual property professionals in North America, the AIPLA Spring Meeting is a hub for high-level discussion on the legislative and judicial trends shaping the future of IP. This year's program highlights the intersection of innovation and technology, with a deep focus on "The Future of IP in an AI-Driven World."

If you or your firm will be in San Francisco for AIPLA2026, Jennifer would be delighted to meet to discuss cross-border patent strategies or our specialized services in China. Please reach out to us to schedule a meeting during the conference.

我們過去活動

Recommended Insights

FOLLOW UP: Amendments to the China Patent Examination Guidelines in 2022 – Part 1: New rules for designs in view of China signing onto the Hague Agreement

2023年1月4日
Since the publication of our earlier article about China signing onto the Hague Agreement, some of our Hong Kong clients have expressed interest in taking advantage of the Hague international design application system, i.e., filing a Hague international design application with the CNIPA (Chinese National Intellectual Property Administration) as a receiving office (RO). Up until […]

Do Promotional Marketing Materials Constitute an “Offer for Sale” under Chinese Patent Law? Bayer IP GmbH v. Nanjing Hang Seng Pharmaceutical

2023年12月12日
Bayer's blockbuster drug Rivaroxaban has seen its share of patent litigations in China, several of which are big enough to be listed as Top 10 IP cases or 50 Representative IP cases. We summarized an invalidation case back in 2020 where all of Bayer’s claims directed towards the compound were upheld. Recently, another Rivaroxaban case […]

Diagnostic Claims in China

2020年1月9日
The Chinese Patent Law excludes patenting methods of diagnosing or treating a disease. More specifically, this refers to processes of identifying, determining, or eliminating the cause or focus of diseases which are practiced directly on living human or animal bodies. Please keep in mind that instruments used for implementing these methods are still patentable. So […]

IP Strategies for the Newly Released Implementation Regulations of the 4th Amendment of the Chinese Patent Law: Part 2: Grace Period without Loss of Novelty

2024年2月7日
Background As mentioned in our earlier article, the Implementation Regulations of the Chinese Patent Law (“Regulations”, similar to the CFR in the US) were approved in November, and the CNIPA finally made public the full text of the Regulations just before the arrival of the New Year. At the same time, the CNIPA also released […]
Top crossarrow-right